JP2021155415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021155415A5 JP2021155415A5 JP2021049350A JP2021049350A JP2021155415A5 JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5 JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fluorobenzyl
- pyridin
- oxy
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025083688A JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000787P | 2020-03-27 | 2020-03-27 | |
| US63/000787 | 2020-03-27 | ||
| US202063126113P | 2020-12-16 | 2020-12-16 | |
| US63/126113 | 2020-12-16 | ||
| US202163135870P | 2021-01-11 | 2021-01-11 | |
| US63/135870 | 2021-01-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Division JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021155415A JP2021155415A (ja) | 2021-10-07 |
| JP2021155415A5 true JP2021155415A5 (enExample) | 2024-03-21 |
Family
ID=75252595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049350A Ceased JP2021155415A (ja) | 2020-03-27 | 2021-03-24 | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230201185A1 (enExample) |
| EP (2) | EP4537816A3 (enExample) |
| JP (2) | JP2021155415A (enExample) |
| KR (1) | KR20220157486A (enExample) |
| CN (1) | CN115348863A (enExample) |
| AU (1) | AU2021244918A1 (enExample) |
| BR (1) | BR112022017578A2 (enExample) |
| CA (1) | CA3176569A1 (enExample) |
| ES (1) | ES3031577T3 (enExample) |
| IL (1) | IL296694A (enExample) |
| MX (1) | MX2022010811A (enExample) |
| TW (1) | TWI823072B (enExample) |
| WO (1) | WO2021191812A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| CA3246495A1 (en) * | 2022-03-25 | 2023-09-28 | Ildong Pharmaceutical Co., Ltd. | NEW GLP-1 RECEPTOR AGONIST COMPOUND SALT, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION INCLUDING IT |
| KR20250036254A (ko) * | 2022-07-22 | 2025-03-13 | 화이자 인코포레이티드 | 2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일}피페리딘-1-일｝메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카복실산,1,3-다이하이드록시-2-(하이드록시메틸)프로판-2-아민 염의 제조를 위한 방법 및 중간체 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN116675680B (zh) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | 一种氘代化合物及其制备方法、药物和应用 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025224648A1 (en) * | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| TW202612693A (zh) * | 2024-06-05 | 2026-04-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1受體激動劑的口服藥物組合物及其製備方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| PT1334721E (pt) * | 2000-10-24 | 2009-06-01 | Ajinomoto Kk | Preparações de fármacos hidrofílicos contendo nateglinida |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| DK2621493T3 (en) | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TWI538748B (zh) * | 2011-11-16 | 2016-06-21 | 鴻海精密工業股份有限公司 | 鏡頭除塵裝置 |
| WO2013117963A1 (en) * | 2012-02-09 | 2013-08-15 | Piramal Enterprises Limited | Stable oral tablet dosage form of an antidiabetic compound |
| AU2015204597B2 (en) * | 2014-01-09 | 2020-04-30 | Pfizer Inc. | Compositions and methods for treatment of abnormal cell growth |
| JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| TN2018000198A1 (en) | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| JP2019512537A (ja) * | 2016-03-31 | 2019-05-16 | ルピン・リミテッド | ダパグリフロジンの医薬組成物 |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
-
2021
- 2021-03-24 MX MX2022010811A patent/MX2022010811A/es unknown
- 2021-03-24 CN CN202180024485.6A patent/CN115348863A/zh active Pending
- 2021-03-24 CA CA3176569A patent/CA3176569A1/en active Pending
- 2021-03-24 BR BR112022017578A patent/BR112022017578A2/pt not_active Application Discontinuation
- 2021-03-24 AU AU2021244918A patent/AU2021244918A1/en not_active Abandoned
- 2021-03-24 EP EP24223164.5A patent/EP4537816A3/en not_active Withdrawn
- 2021-03-24 US US17/906,651 patent/US20230201185A1/en not_active Abandoned
- 2021-03-24 EP EP21714685.1A patent/EP4125896B1/en active Active
- 2021-03-24 WO PCT/IB2021/052430 patent/WO2021191812A1/en not_active Ceased
- 2021-03-24 IL IL296694A patent/IL296694A/en unknown
- 2021-03-24 KR KR1020227036905A patent/KR20220157486A/ko not_active Withdrawn
- 2021-03-24 JP JP2021049350A patent/JP2021155415A/ja not_active Ceased
- 2021-03-24 ES ES21714685T patent/ES3031577T3/es active Active
- 2021-03-24 TW TW110110639A patent/TWI823072B/zh not_active IP Right Cessation
-
2025
- 2025-05-20 JP JP2025083688A patent/JP2025118943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512117A5 (enExample) | ||
| MX2022010811A (es) | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| IL275982B2 (en) | Pharmaceutical compositions for treating cystic fibrosis | |
| JP2008515905A5 (enExample) | ||
| US20140235558A1 (en) | Pharmaceutical composition having activity of anticancer | |
| JP6068765B2 (ja) | 薬学的複合製剤 | |
| WO2004030700A1 (ja) | 固形製剤 | |
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むｐＨ依存性薬物放出特性が改善した剤形 | |
| JP2023536667A5 (enExample) | ||
| JP2023532223A5 (enExample) | ||
| JP4786127B2 (ja) | 色素沈着改善治療薬 | |
| JP2022537685A5 (enExample) | ||
| CN103800336A (zh) | 一种具有抗血栓活性药物的组合物 | |
| CN101766611B (zh) | 一种左旋氨氯地平或其可药用盐和β受体阻滞剂的药物组合物及其应用 | |
| CN113181180A (zh) | 一种缬沙坦氨氯地平缓释片的制备方法 | |
| WO2010009619A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| KR101497354B1 (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| JP7695724B2 (ja) | 医薬組成物およびその適用 | |
| CN101663035A (zh) | 4－环丙基甲氧基－n－(3,5－二氯代－1－环氧－吡啶－4－基)－5－(甲氧基)吡啶－2－甲酰胺用于治疗与帕金森症有关的运动障碍的用途 | |
| TWI351957B (en) | Prolonged-release diuretic compositions | |
| CN102058591A (zh) | 一种左旋氨氯地平和替米沙坦的复方制剂 | |
| JP2024503689A5 (enExample) | ||
| CN101785781B (zh) | 一种左旋氨氯地平或其可药用盐和黑木耳多糖的药物组合物及其应用 |